Kazia Advances Paxalisib in Rare Seizure Disorders
Sydney, Australia, September 21, 2026 Kazia Therapeutics Limited has announced that its development partner Sovargen Co., Ltd. has dosed...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Sydney, Australia, September 21, 2026 Kazia Therapeutics Limited has announced that its development partner Sovargen Co., Ltd. has dosed...
BOSTON, Mass. — September 21, 2026 Tiziana Life Sciences announced that the last patient has completed the last visit...
VANCOUVER, Canada — September 17, 2026 Clearmind Medicine announced that its Chief of Global Impact, Mary-Elizabeth Gifford, testified at...
MIAMI, Fla. — September 17, 2026 MIRA Pharmaceuticals announced that its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral...
Toronto, Ontario, Canada, September 16, 2026 Thryv Therapeutics has announced the publication of new research in JACC: Heart Failure...
WALTHAM, Mass. — September 14, 2026 Sionna Therapeutics, Inc. announced plans to advance its preferred proprietary dual combination of...
SAN DIEGO, California — September 8, 2026 Artiva Biotherapeutics, Inc. announced planned clinical data disclosures and development milestones for...
RESEARCH TRIANGLE PARK, N.C., September 2, 2026 Opus Genetics, Inc. plans to present topline clinical data from Cohort 1...
TEL AVIV, Israel, September 2, 2026 Teva Pharmaceutical Industries Ltd. has reported positive topline results from its ongoing Phase...
Ramat Gan, Israel — August 17, 2026 Can-Fite BioPharma Ltd. announced new preclinical findings showing that namodenoson enhanced the...
